Please assess the completion status of the following clinical trial:

Trial Title: Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Ph-positive (Ph+) Chronic Myelogenous Leukemia in chronic, accelerated or blast phase or Ph+ acute lymphoblastic leukemia (ALL) with imatinib-resistant disease or intolerance to imatinib.~* Ph-negative acute leukemia in second or subsequent relapse~* Age \>1 and \<21 years~* Lansky or Karnofsky scale \>60~* Life expectancy \>3 weeks~* Adequate hepatic and renal function~* Written informed consent~Exclusion Criteria:~* Subjects for whom potentially-curative therapy was available, including electing immediate \[ie, planned \<45 days\] stem-cell transplantation. Subjects in Stratum 1 were to have had an ongoing identical HLA donor search, and may have discontinued study if a donor became available.)~* Subjects with symptomatic central nervous system (CNS) disease (eg, convulsions due to their CNS disease).~* Subjects who had not recovered from acute toxicity of previous therapy.~* Clinically-significant disorder of platelet function (eg, von Willebrand's disease) or ongoing gastrointestinal bleeding.~* Serious uncontrolled medical disorder or active infection~* Uncontrolled or significant cardiovascular disease~* Use of any investigational agent or any other anticancer agent within 14 days prior to treatment start.~* Prior therapy with dasatinib~* Subjects taking medications that irreversibly inhibit platelet function or anticoagulants.~* Subjects taking certain medications that are accepted to have a risk of causing QTc prolongation.~* Women of Child Bearing Potential with a positive pregnancy test prior to study drug administration.~* Expected noncompliance, or unable to have regular follow-up due to psychologic, social, familial, or geographic reasons.~* Subjects who are compulsorily detained for legal reasons or treatment of either a psychiatric or physical (eg, infectious disease) illness must not be enrolled into this study.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Stratum 1 (Ph+ CP-CML) (Type: EXPERIMENTAL): Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
- Stratum 2/3 (Ph+ ALL or AP/BP-CML) (Type: EXPERIMENTAL): Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
- Stratum 4 (Ph- ALL/AML) (Type: EXPERIMENTAL): Participants with second or subsequent relapse of Ph- ALL or Ph- AML

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete